Inhaled insulin: where are we and where might we go?

Aidan McElduff and Dennis K Yue
Med J Aust 2007; 186 (8): . || doi: 10.5694/j.1326-5377.2007.tb00970.x
Published online: 16 April 2007

Inhalation is an attractive alternative to injection, but significant issues will limit its use

Insulin is an excellent therapeutic agent with few significant side effects, apart from hypoglycaemia. However, it has one major disadvantage — it needs to be given by injection. Patients’ fears or reservations often mean doctors are reluctant to initiate insulin therapy, even when it is clearly indicated.

  • Aidan McElduff1
  • Dennis K Yue2,3

  • 1 Department of Endocrinology, Royal North Shore Hospital, Sydney, NSW.
  • 2 University of Sydney, Sydney, NSW.
  • 3 Royal Prince Alfred Hospital, Sydney, NSW.


Competing interests:

Aidan McElduff has performed clinical trials on inhaled insulin for Novo Nordisk, and has received support from Eli Lilly and Novo Nordisk to attend meetings. Dennis Yue has performed clinical trials on inhaled insulin for Pfizer, and staff in his department have performed clinical trials for Novo Nordisk. He is also on the Global Advisory Panel of Pfizer for inhaled insulin, and has received support from Eli Lilly, Novo Nordisk, and Pfizer to attend meetings.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.